<DOC>
	<DOC>NCT01627665</DOC>
	<brief_summary>The study will address the impact of genetical variation of a protein involved in the intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.</brief_summary>
	<brief_title>Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban</brief_title>
	<detailed_description>The study will address the impact of genetical variation of a protein involved in the intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.</detailed_description>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Healthy participants Aged between 1835 years inclusive Male Caucasian Body mass index (BMI) between 18 and 27 kg per mÂ² inclusive.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>dabigatran</keyword>
	<keyword>rivaroxaban</keyword>
	<keyword>PKC</keyword>
	<keyword>PKD</keyword>
	<keyword>p-glycoprotein</keyword>
	<keyword>polymorphism</keyword>
</DOC>